NEW YORK, Sept. 30, 2016 /PRNewswire/ -- The following
statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise
acquired securities of Keryx Biopharmaceuticals, Inc. (NASDAQ:
KERX) between February 25, 2016
and August 1, 2016. You are
hereby notified that a securities class action lawsuit has been
commenced in the USDC for the Southern District of New York. To get more information go
to:
http://www.zlk.com/pslra/keryx-biopharmaceuticals-inc
or contact Joseph E. Levi, Esq.
either via email at jlevi@zlk.com or by telephone at (212)
363-7500, toll-free: (877) 363-5972. There is no cost or
obligation to you.
The complaint alleges that throughout the Class Period,
Defendants made materially false and/or misleading statements, as
well as failed to disclose material adverse facts about the
Company's business, operations, and prospects. Specifically,
Defendants made false and/or misleading statements and/or failed to
disclose: (1) that the Company was experiencing production-related
difficulties in converting API to finished drug product; (2) that
the issue was resulting in decreased production yields of finished
drug product; (3) that, as a result, the Company would, and did
exhaust its reserve of finished drug product; and (4) that, as a
result of the foregoing, Defendants' statements about Keryx's
business, operations, and prospects, were false and misleading
and/or lacked a reasonable basis.
If you suffered a loss in Keryx Biopharmaceuticals, Inc. you
have until October 3, 2016 to
request that the Court appoint you as lead plaintiff. Your ability
to share in any recovery doesn't require that you serve as a lead
plaintiff.
Levi & Korsinsky is a national firm with offices in
New York, New Jersey, California, Connecticut, and Washington D.C. The firm's attorneys have
extensive expertise and experience representing investors in
securities litigation, and have recovered hundreds of millions of
dollars for aggrieved shareholders. Attorney advertising. Prior
results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY
10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
Logo -
http://photos.prnewswire.com/prnh/20120409/MM84375LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/upcoming-deadline-levi--korsinsky-llp-notifies-shareholders-of-keryx-biopharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-3-2016--kerx-300337298.html
SOURCE Levi & Korsinsky, LLP